← Back to Search

positron emission tomography for Prostate Cancer

N/A

Waitlist Available

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial is testing whether a new imaging procedure, PET scan, can improve the ability to detect new or recurrent prostate cancer.

Eligible Conditions

Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Comparison of the sensitivity of PET imaging with FDG with standard of care diagnostic methods

Brain Diseases, Metabolic

Pharmacokinetics

Side effects data

From 2010 Phase 1 & 2 trial • 52 Patients • NCT00095940

100%

Diarrhea

50%

Vomiting

50%

Phosphate, serum-low (hypophosphatemia)

50%

Anorexia

50%

Potassium, serum-low (hypokalemia)

50%

Lymphopenia

50%

Albumin, serum-low (hypoalbuminemia)

50%

Dehydration

100%

80%

60%

40%

20%

Study treatment Arm

Medulloblastoma: Lapatinib Prior to Surgery

Medulloblastoma: No Lapatinib Prior to Surgery

Medulloblastoma: No Surgery

High Grade Glioma: No Surgery

Ependymoma: Lapatinib Prior to Surgery

Ependymoma: No Lapatnib Prior to Surgery

Ependymoma: No Surgery

Trial Design

1Treatment groups

Experimental Treatment

Group I: PET ScanExperimental Treatment3 Interventions

Each patient receives C11-methionine intravenously. PET imaging begins immediately after injection for approximately 60 minutes total using standard imaging procedures. Immediately following the completion of imaging after C11-methionine administration, each patient receives FDG intravenously. PET imaging begins approximately 45 minutes thereafter for approximately 60 minutes using standard imaging procedures.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

positron emission tomography

2010

Completed Phase 2

~1370

fludeoxyglucose F 18

2005

Completed Phase 3

~3970

methionine C 11

1997

N/A

~180

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,933 Previous Clinical Trials

585,449 Total Patients Enrolled

132 Trials studying Prostate Cancer

51,901 Patients Enrolled for Prostate Cancer

National Cancer Institute (NCI)NIH

13,657 Previous Clinical Trials

40,933,494 Total Patients Enrolled

560 Trials studying Prostate Cancer

507,000 Patients Enrolled for Prostate Cancer

Steven M. Larson, MDStudy ChairMemorial Sloan Kettering Cancer Center

1 Previous Clinical Trials

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do applicants over the age of twenty qualify for participation in this research study?

"According to the eligibility requirements, this clinical trial is open for those aged 0 through 120. 76 trials are available for minors and 1315 have been created to aid seniors in seeking treatment options."

Answered by AI

For whom is this research trial suitable?

"This medical study seeks participants with prostate cancer that are of any age from birth to 120 years old. Overall, the trial wishes to enroll 173 patients in total."

Answered by AI

Are there any volunteers actively being sought for this research endeavor?

"Per information published on clinicaltrials.gov, this trial is not accepting enrollees at the present moment. It was first posted in 1997 and last updated earlier this year; however, 1321 other trials are currently open to participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

PET Scan in Treating Patients With Metastatic Prostate Cancer

1997. "PET Scan in Treating Patients With Metastatic Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00002981.